InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.
Jim has been the founder, inventor, investor, and owner operator in many med-tech / biotech ventures. Having started and operated over 8 different companies since 1990,Jim began working on the Matrix technology, the backbone for InSitu’s sustained release drug, AnestaGel, in 2007 and co-founded InSitu Biologics in 2014. Xerox trained out of college, Jim specializes in the total operation for small companies.
President & CEO
InSitu Biologics, Inc